| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 9.23▼ | 8.88▲ | 8.61▲ | 7.82▲ | 5.93▲ |
| MA10 | 9.13▼ | 8.42▲ | 8.38▲ | 6.90▲ | 5.01▲ |
| MA20 | 8.75▲ | 8.20▲ | 7.87▲ | 5.38▲ | 5.21▲ |
| MA50 | 8.32▲ | 7.63▲ | 7.30▲ | 4.58▲ | 2.45▲ |
| MA100 | 7.71▲ | 6.78▲ | 5.71▲ | 4.75▲ | 3.58▲ |
| MA200 | 7.84▲ | 5.28▲ | 4.73▲ | 2.67▲ | 4.26▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | 0.105▲ | 0.106▲ | 0.429▲ | 0.323▲ |
| RSI | 56.666▲ | 63.798▲ | 64.284▲ | 71.097▲ | 76.612▲ |
| STOCH | 64.995 | 78.572 | 65.769 | 70.059 | 47.530 |
| WILL %R | -57.806 | -39.595 | -31.787 | -14.259▲ | -13.472▲ |
| CCI | -7.019 | 123.410▲ | 149.821▲ | 113.313▲ | 233.134▲ |
|
Monday, December 01, 2025 10:00 AM
Verrica Pharmaceuticals (Nasdaq: VRCA) raised approximately $50 million through a private investment in public equity, a move the company said will retire its debt facility, strengthen ...
|
|
Wednesday, November 26, 2025 10:55 AM
Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive ...
|
|
Monday, November 24, 2025 05:16 AM
Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027Financing anchored by Caligan Partners LP and PBM Capital, along ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 05/12/25 | 8.42 | 9.625 | 7.895 | 8.94 | 313,791 |
| 04/12/25 | 7.43 | 8.475 | 7.20 | 8.42 | 195,329 |
| 03/12/25 | 6.68 | 7.60 | 6.5719 | 7.48 | 179,096 |
| 02/12/25 | 7.29 | 7.50 | 6.2601 | 6.73 | 361,695 |
| 01/12/25 | 7.99 | 8.1835 | 7.30 | 7.55 | 851,623 |
| 28/11/25 | 7.30 | 9.8212 | 6.92 | 9.10 | 2,621,454 |
| 26/11/25 | 5.56 | 6.79 | 5.50 | 6.71 | 1,155,147 |
| 25/11/25 | 4.81 | 5.32 | 4.73 | 5.12 | 269,600 |
| 24/11/25 | 4.41 | 5.18 | 4.40 | 4.72 | 581,878 |
| 21/11/25 | 4.09 | 4.26 | 3.90 | 4.21 | 53,249 |
|
|
||||
|
|
||||
|
|